PRIMARY STUDY

Is There a Legitimate Role for the Therapeutic Use of Cannabinoids for Symptom Management in Chronic Kidney Disease?

Key Findings:  To realize the therapeutic potential suggested by preclinical data, it is likely that, in managing the symptom burden in CKD, both CB1R and CB2R agonists, alone or in combination with each other and/or with CBD, and ultimately, the endocannabinoid system, will have to be targeted to achieve effective symptom control without dose-limiting adverse effects.